Protara Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 2, 2024. Protara is a clinical-stage biopharmaceutical company developing TARA-002 for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral nutrition. It has no approved products and has not generated product revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.75 million | $5.14 million |
| General and administrative expense | $4.10 million | $4.59 million |
| Total operating expenses / operating loss | $11.85 million | $9.73 million |
| Interest and investment income | $0.76 million | $0.69 million |
| Net loss | $11.10 million; $0.97 per share | $9.05 million; $0.80 per share |
| Operating cash used | $10.38 million | $12.89 million |
| Cash, cash equivalents and marketable debt securities | $55.22 million | $65.58 million at Dec. 31, 2023 |
| Working capital | $52.4 million | Not stated for comparable date |
| Total liabilities | $9.73 million, including $5.23 million of operating lease liabilities | $10.63 million at Dec. 31, 2023 |
Margins are not meaningful because the company has no revenue. Management reported sufficient financial resources for at least 12 months from the filing date, while also stating that additional capital will be needed to fully fund its plans. The company reported no debt financing; reported liabilities include operating leases.
Material changes and cash flows
- Net loss increased $2.05 million year over year, as operating expenses rose $2.12 million. R&D increased $2.61 million, primarily from higher TARA-002 clinical and nonclinical activity ($1.8 million) and personnel costs ($1.1 million), partly offset by $0.3 million lower Choline development activity.
- G&A declined $0.49 million, mainly from lower personnel-related expense. Investment income increased $0.07 million, primarily due to higher money-market rates.
- Operating cash use was $2.51 million lower year over year, largely reflecting working-capital timing, despite the higher net loss. Investing activities provided $23.1 million, mainly from maturities of marketable securities; financing activities used $0.08 million.
- Cash and marketable securities together declined about $10.4 million from year-end. Cash and cash equivalents alone increased to $52.23 million, in part as marketable securities matured.
Outlook, developments and risks
- TARA-002 in NMIBC: The company reported April 2024 pooled three-month results for 16 evaluable CIS patients across three studies: 6 complete responses (38%) overall, including 5/8 (63%) in CIS-only patients and 1/8 (13%) in CIS plus Ta/T1 patients. These are small, early-stage, pooled results, not confirmatory efficacy evidence. The company expects preliminary results from a planned six-month risk-benefit analysis of about 10 patients in ADVANCED-2 in the second half of 2024.
- IV Choline Chloride: In April 2024, Protara reported FDA alignment on a potential registrational path: a single study measuring restoration of choline levels may support a regulatory filing. The company plans to develop the product for adult and adolescent patients on long-term parenteral nutrition.
- Lymphatic malformations: The Phase 2 STARBORN-1 trial, initiated in October 2023, is planned to enroll approximately 30 pediatric patients.
- Subsequent financing: On April 10, 2024, the company closed a private placement for approximately $42.0 million net proceeds. It issued 9,143,380 common shares and pre-funded warrants for 1,700,000 shares, with accompanying warrants for up to 10,843,380 shares at $5.25 each. The financing extends liquidity but creates substantial potential dilution; warrant proceeds are uncertain and depend on exercise.
- Protara expects continued significant development expenses and operating losses and may need further financing. Capital-market conditions, trial progress, clinical outcomes, manufacturing, regulatory decisions and the ability to raise funds on acceptable terms are key risks. The filing reports no material change to previously disclosed risk factors apart from financing and warrant-related risks.
- Management said disclosure controls were effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported. No legal proceeding was identified as likely to have a material adverse effect.
Important facts for investors to verify
- Confirm the scope, follow-up and patient composition underlying the reported 16-patient pooled NMIBC results, and track the ADVANCED-2 six-month analysis and subsequent trial data.
- Review the terms and potential dilution from the April placement, including exercise conditions and expiration provisions for the common warrants and the near-nominal exercise price of the pre-funded warrants.
- Assess the company’s cash runway against clinical, manufacturing and operating plans; the filing’s 12-month liquidity statement does not eliminate the need for future financing.
- Monitor FDA requirements and timing for IV Choline Chloride, and enrollment and outcomes for the TARA-002 programs.